sdb-005 sdb-005 sdb-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. it is presumed to be an agonist of the cb1 and cb2 cannabinoid receptors. sdb-005 is the indazole core analog of pb-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group. sdb-005legal statuslegal status ca: schedule ii de: npsg (industrial and scientific use only) uk: class b identifiers iupac name naphthalen-1-yl 1-pentyl-1h-indazole-3-carboxylate cas number2180934-13-6 ypubchem cid125181303chemspider30922481uniiz6xwv5u765chemical and physical dataformulac23h22n2o2molar mass358.441 g·mol−13d model (jsmol)interactive image smiles cccccn1n=c(c(=o)oc2=cc=cc3=c2c=cc=c3)c2=c1c=cc=c2 inchi inchi=1s/c23h22n2o2/c1-2-3-8-16-25-20-14-7-6-13-19(20)22(24-25)23(26)27-21-15-9-11-17-10-4-5-12-18(17)21/h4-7,9-15h,2-3,8,16h2,1h3key:jbvnfkzvdlfoay-uhfffaoysa-n the code number sdb-005 was originally used for a different compound, the n-phenyl instead of n-benzyl analogue of sdb-006. this compound is a potent agonist of the cb1 receptor (ki = 21 nm) and cb2 receptor (ki = 140 nm). original, non designer drug sdb-005 however, sdb-005 was subsequently used as the name for the indazole-3-carboxylate compound mentioned above when it was sold in europe as a designer drug, and was entered into the emcdda synthetic drug database under this name. consequently, there are now two distinct, yet fairly closely related cannabinoid compounds, which may both be referred to under the code sdb-005.